MX354571B - Genomas lentivirales quimericos no integrativos como vacunas innovadoras contra el virus de la inmunodeficiencia humana tipo 1 (vih-1). - Google Patents

Genomas lentivirales quimericos no integrativos como vacunas innovadoras contra el virus de la inmunodeficiencia humana tipo 1 (vih-1).

Info

Publication number
MX354571B
MX354571B MX2014002953A MX2014002953A MX354571B MX 354571 B MX354571 B MX 354571B MX 2014002953 A MX2014002953 A MX 2014002953A MX 2014002953 A MX2014002953 A MX 2014002953A MX 354571 B MX354571 B MX 354571B
Authority
MX
Mexico
Prior art keywords
retrovirus
chimeric non
against hiv
vaccines against
nucleic acid
Prior art date
Application number
MX2014002953A
Other languages
English (en)
Other versions
MX2014002953A (es
Inventor
Chebloune Yahia
Aldebert Delphine
Arrode-Bruses Géraldine
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Publication of MX2014002953A publication Critical patent/MX2014002953A/es
Publication of MX354571B publication Critical patent/MX354571B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a los ácidos nucleicos que comprenden los genomas retrovirales quiméricos no integrativos que comprenden las secuencias terminales repetidas (LTR) 5' y 3' de lentivirus caprino: el virus de la Artritis-Encefalitis Caprina (CAEV) o de otro retrovirus que no se integra en las células humanas y al menos un gen viral de otro retrovirus. La invención se refiere igualmente a un vector que comprende un ácido nucleico tal, una composición inmunogénica o de vacuna que comprende el vector o el ácido nucleico, así como su utilización para el tratamiento y/o la prevención de una infección por un retrovirus o una enfermedad inducida por un agente patógeno.
MX2014002953A 2011-09-12 2012-09-12 Genomas lentivirales quimericos no integrativos como vacunas innovadoras contra el virus de la inmunodeficiencia humana tipo 1 (vih-1). MX354571B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1158096A FR2979919B1 (fr) 2011-09-12 2011-09-12 Genomes lentiviraux chimeriques non-integratifs comme vaccins innovants contre vih-1
PCT/EP2012/067863 WO2013037841A2 (fr) 2011-09-12 2012-09-12 Génomes lentiviraux chimériques non-intégratifs comme vaccins innovants contre le hiv-1

Publications (2)

Publication Number Publication Date
MX2014002953A MX2014002953A (es) 2014-07-10
MX354571B true MX354571B (es) 2018-03-12

Family

ID=46829786

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002953A MX354571B (es) 2011-09-12 2012-09-12 Genomas lentivirales quimericos no integrativos como vacunas innovadoras contra el virus de la inmunodeficiencia humana tipo 1 (vih-1).

Country Status (10)

Country Link
US (1) US9879230B2 (es)
EP (1) EP2756087A2 (es)
JP (1) JP6324892B2 (es)
CN (1) CN103946385B (es)
CA (1) CA2848484C (es)
FR (1) FR2979919B1 (es)
IL (1) IL231494B (es)
MX (1) MX354571B (es)
WO (1) WO2013037841A2 (es)
ZA (1) ZA201402676B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6622326B2 (ja) 2015-05-04 2019-12-18 エピバックス インコーポレーテッド インフルエンザａ／上海／２／２０１３ ｈ７配列の改変ｈ７赤血球凝集素糖タンパク質
US20180179256A1 (en) * 2015-05-04 2018-06-28 Epivax, Inc. Modified H7 Hemagglutinin Glycoprotein of the Influenza A/Shanghai/2/2013 H7 Sequence
JP7098521B2 (ja) * 2015-11-24 2022-07-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド レトロウイルス産生のための安定な細胞株
TW202430633A (zh) * 2022-12-07 2024-08-01 科羅拉多大學董事會法人團體 新穎的ｈｉｖ－１變異體及其在動物激發模型中的使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
JPH09510361A (ja) * 1994-03-24 1997-10-21 シンジェニックス・リミテッド パッケージング欠陥性レンチウイルス
US7488485B2 (en) * 2003-09-16 2009-02-10 University Of Kansas Medical Center DNA vaccine compositions and methods of use
US6602505B2 (en) * 1998-04-30 2003-08-05 University Of Southern California Viral chimeras comprised of CAEV and HIV-1 genetic elements
DE102005003207A1 (de) * 2005-01-17 2006-07-27 Geneering Gmbh Lentivirales Gentransfersystem für Ribozym-vermittelte RNA-Reparatur

Also Published As

Publication number Publication date
WO2013037841A2 (fr) 2013-03-21
CA2848484C (fr) 2021-03-23
JP6324892B2 (ja) 2018-05-16
WO2013037841A3 (fr) 2013-05-23
CN103946385A (zh) 2014-07-23
ZA201402676B (en) 2015-05-27
FR2979919A1 (fr) 2013-03-15
FR2979919B1 (fr) 2015-12-11
MX2014002953A (es) 2014-07-10
EP2756087A2 (fr) 2014-07-23
IL231494A0 (en) 2014-04-30
IL231494B (en) 2018-05-31
US20140370051A1 (en) 2014-12-18
CA2848484A1 (fr) 2013-03-21
JP2014527812A (ja) 2014-10-23
CN103946385B (zh) 2016-03-16
US9879230B2 (en) 2018-01-30

Similar Documents

Publication Publication Date Title
CY1124043T1 (el) Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
NZ602504A (en) Antiviral vaccines with improved cellular immunogenicity
MX2016002586A (es) Métodos y composiciones para el tratamiento guiado por rna de infección por hiv.
AU2011257555A8 (en) Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains
EA201890012A1 (ru) Способы и композиции для рнк-направляемого лечения инфекции, вызываемой вич
JP2012509340A5 (es)
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
ATE527281T1 (de) Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
NZ729150A (en) Antiretroviral agents
HK1207871A1 (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
EP4043031A3 (en) Zika viral antigen constructs
SG178909A1 (en) Generation of a broad t-cell response in humans against hiv
EA201290956A1 (ru) Вакцина против вич
MX354571B (es) Genomas lentivirales quimericos no integrativos como vacunas innovadoras contra el virus de la inmunodeficiencia humana tipo 1 (vih-1).
PH12014500369A1 (en) Influenza h5 vaccines
WO2011038473A8 (pt) Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos
NI201700080A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas.
AU2017261706A1 (en) Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
SI2678351T1 (en) HIV-GP-120-VARIANTA
ZA201900641B (en) Viral vaccines
PH12013501728A1 (en) Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv
WO2009126308A3 (en) Compositions and methods for vaccine and virus production
WO2007137591A8 (en) Hiv vaccine
GB201008123D0 (en) Novel compounds

Legal Events

Date Code Title Description
FG Grant or registration